Genomic Vision Announces the Convening of an Extraordinary Shareholders’ Meeting on February 15, 2019, and Provides an Update on Its Financial Situation  Business Wire

Regulatory News: Genomic Vision (Paris:GV) (FR0011799907 – GV), a company specialized in the development of in-vitro diagnostic (IVD) tests for the ea.